SecSonar.com

GRAIL, Inc. (GRAL)

GRAIL, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

GRAIL, Inc. (GRAL) is a Medical - Diagnostics & Research company based in US with a market capitalization of $3.1B. Revenue grew 17.2% year-over-year and free cash flow was negative at -$299.9M. This page tracks GRAL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 1K employees · IPO Jun 12, 2024

Valuation

Valuation & price

$59.65 · as of May 17, 2026 · -48.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.21

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$116$73.74$31.42Jul 25Dec 25Jun 26Jul 7, 25$44.85Jul 9, 25$42.13Jul 11, 25$40.73Jul 15, 25$38.53Jul 17, 25$35.92Jul 21, 25$34.35Jul 23, 25$40.88Jul 25, 25$40.29Jul 29, 25$34.12Jul 31, 25$34.21Aug 4, 25$33.23Aug 6, 25$33.08Aug 8, 25$32.82Aug 12, 25$33.60Aug 14, 25$32.18Aug 19, 25$31.42Aug 21, 25$33.15Aug 25, 25$32.92Aug 27, 25$33.63Aug 29, 25$32.79Sep 3, 25$32.42Sep 5, 25$36.91Sep 9, 25$37.53Sep 11, 25$38.65Sep 15, 25$39.33Sep 17, 25$38.32Sep 19, 25$41.65Sep 23, 25$46.98Sep 25, 25$48.26Sep 29, 25$58.77Oct 2, 25$64.73Oct 6, 25$61.70Oct 8, 25$72.79Oct 10, 25$66.13Oct 14, 25$69.29Oct 16, 25$86.41Oct 20, 25$91.85Oct 22, 25$79.76Oct 24, 25$89.39Oct 28, 25$86.36Oct 30, 25$91.15Nov 3, 25$89.81Nov 5, 25$84.64Nov 7, 25$79.40Nov 11, 25$83.39Nov 14, 25$79.63Nov 18, 25$81.46Nov 20, 25$85.65Nov 24, 25$111.40Nov 26, 25$110.16Dec 1, 25$98.27Dec 3, 25$101.19Dec 5, 25$100.98Dec 9, 25$97.46Dec 11, 25$95.06Dec 15, 25$91.04Dec 17, 25$85.87Dec 19, 25$91.09Dec 23, 25$91.39Dec 26, 25$91.59Dec 31, 25$85.59Jan 5, 26$95.75Jan 7, 26$103.59Jan 9, 26$100.10Jan 13, 26$101.97Jan 15, 26$97.44Jan 20, 26$101.31Jan 22, 26$116.06Jan 26, 26$106.31Jan 28, 26$101.00Jan 30, 26$97.82Feb 3, 26$105.42Feb 5, 26$94.06Feb 9, 26$100.40Feb 11, 26$100.40Feb 17, 26$99.03Feb 19, 26$101.53Feb 23, 26$43.03Feb 25, 26$51.79Feb 27, 26$53.23Mar 3, 26$52.76Mar 5, 26$51.80Mar 9, 26$49.82Mar 11, 26$46.33Mar 13, 26$43.06Mar 17, 26$47.37Mar 19, 26$48.47Mar 23, 26$49.13Mar 25, 26$52.29Mar 27, 26$48.49Apr 1, 26$53.60Apr 6, 26$51.74Apr 8, 26$50.78Apr 10, 26$45.63Apr 14, 26$50.49Apr 16, 26$49.47Apr 20, 26$51.20Apr 22, 26$52.60Apr 24, 26$54.42Apr 28, 26$52.20Apr 30, 26$54.48May 4, 26$55.66May 6, 26$62.75May 8, 26$61.64May 12, 26$61.98May 15, 26$59.65May 19, 26$60.99May 21, 26$67.86May 26, 26$68.96May 28, 26$73.92Jun 1, 26$64.40Jun 3, 26$61.13Jun 5, 26$59.98Jun 9, 26$60.90Jun 11, 26$60.16Jun 15, 26$59.81Jun 17, 26$59.45Jun 22, 26$62.10Jun 24, 26$64.58Jun 30, 26$67.74
$31.4252-week range$116.06
Loading valuation history…

Fundamentals

Key fundamentals

$3.1B

Market cap

17.2%

Revenue growth (YoY)

-42.5%

Gross margin

-$299.9M

Free cash flow (USD)

-$806.4M

Net debt

Net cash position

15.2%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$14.6MFY 2022$55.5MFY 2023$93.1MFY 2024$125.6MFY 2025$147.2M
$0$147.2M

Free cash flow by year

2018 → 2025

FY 2018$-225.2MFY 2019$-249.1MFY 2020$-243.9MFY 2021$-758.1MFY 2022$-584.2MFY 2023$-608.7MFY 2024$-582.4MFY 2025$-299.9M
-$225.2M-$299.9M

Gross margin by year

2021 → 2025

FY 2021-684.4%FY 2022-209.6%FY 2023-102.7%FY 2024-62.1%FY 2025-42.5%
-684.4%-42.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

4

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 22, 2026Filing
  • Insider sellInsider Sell $91KPartridge Andrew John · Chief Growth Officer · $91.1KJun 5, 2026Filing
  • 8-K eventCEO AppointmentJun 1, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Insider sellInsider Sell $3.1MOfman Joshua J. · Director, President · $3.1MApr 9, 2026Filing
  • Insider sellInsider Sell $6.2MRAGUSA ROBERT P · Director, Chief Executive Officer · $6.2MApr 9, 2026Filing
  • Insider sellInsider Sell $2.3MFreidin Aaron · Chief Financial Officer · $2.3MApr 9, 2026Filing

Questions

Frequently asked questions

What is GRAIL, Inc.'s market cap?

GRAIL, Inc. (GRAL) has a market capitalization of $3.1B.

What is GRAL's P/E ratio?

A meaningful P/E ratio is not available for GRAL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is GRAL's price-to-book (P/B) ratio?

GRAL trades at 1.21 times book value per share.

Are insiders buying GRAL stock?

SEC Form 4 filings show no open-market insider buys at GRAIL, Inc. in the last 90 days (4 sells).

Same arena

Related companies in Medical - Diagnostics & Research

NEOG

Neogen Corporation

$2B

TWST

Twist Bioscience Corporation

$4.3B

RDNT

RadNet, Inc.

$4.4B

SHC

Sotera Health Company

$4.5B

CDNA

CareDx, Inc

$1.2B

PSNL

Personalis, Inc.

$1B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.